|
| [February 14, 2013] |
 |
VCA Antech, Inc. Reports Fourth Quarter 2012 Results and Provides Financial Guidance for 2013
LOS ANGELES --(Business Wire)--
VCA
Antech, Inc. (NASDAQ: WOOF), a leading animal healthcare
company in the United States and Canada, today reported financial
results for the fourth quarter ended December 31, 2012, as follows:
revenue increased 13.3% to $418.2 million; gross profit increased 14.1%
to $81.8 million; loss per common share of $0.66; and adjusted diluted
earnings per common share of $0.24.
Bob Antin, Chairman and CEO, stated, "We are pleased that we are
experiencing improving revenue growth in both our core Animal Hospital
and Laboratory segments. We are also encouraged that we were able to
increase our same-store gross profit margins in each of those segments.
We are seeing steady improvement and growth in the veterinary market
which bolsters our optimism for our overall growth prospects.
"Our results also included a non-cash impairment charge of $123.6
million, or $79.2 million net of tax, primarily related to the
write-down of goodwill and other long-lived assets in our Vetstreet
business, included in our All Other segments category. As a result of
our 2012 impairment review, we determined that the write-down of
goodwill and long-lived assets was necessary as our fiscal 2012 actual
operating results and cash flow, and projections of future operating
results and cash flow, were significantly lower than previously
forecasted. We do not expect this accounting write-down to affect our
ongoing business or financial performance.
"Vetstreet continues to provide us with an array of product and service
offerings that complement our core business. As well, this business
provides its animal hospital clients valuable services to improve
communication with pet owners which contributes to higher patient
traffic. We are committed to building on our leadership position in the
industry by continuing to offer innovative services to our animal
hospital clients.
"Excluding this charge of $0.90 per common share, adjusted diluted
earnings per common share for the fourth quarter of 2012 was $0.24, a
$0.03 per common share or 14.3% increase over the same period in 2011.
"We also reported our financial results for the twelve months ended
December 31, 2012, as follows: revenue increased 14.4% to $1.7 billion;
gross profit increased 10.8% to $375.0 million; and diluted earnings per
common share of $0.51. The results for the twelve months ended December
31, 2012, included a gain of $5.7 million on our 20% interest in
Associate Veterinary Clinics held at the time we became its sole
non-veterinarian shareholder; a depreciation adjustment of $3.1 million,
or $1.9 million net of tax, related to acquired capital leases; and the
non-cash impairment charge of $123.6 million, or $79.2 million net of
tax, noted above. Excluding these items, adjusted diluted earnings per
common share was $1.36 compared to adjusted diluted earnings per common
share of $1.35 for the prior year.
"Animal Hospital revenue in the fourth quarter of 2012 increased 15.6%,
to $330.1 million, driven by acquisitions made in the past twelve months
and same-store revenue growth of 1.6%. Our same-store gross profit
margin increased to 12.8% from 12.7%, and with the lower margins for
acquired Animal Hospitals, our consolidated gross margin decreased to
12.1%, compared to 12.5% for the prior-year quarter. Our Animal Hospital
operating margin decreased to 9.2%, compared to 10.2%, for the
prior-year quarter. During the quarter, we acquired 11 independent
animal hospitals which had historical combined annual revenue of $26.8
million.
"Laboratory internal revenue in the fourth quarter increased 3.0%, to
$75.1 million, driven by both an increase in the number of requisitions
and the average revenue per requisition. Our Laboratory gross profit
margin increased to 42.2% from 42.0%, and our operating margin increased
from 32.2% to 32.6%.
"Revenue from our All Other segment increased $4.9 million in the fourth
quarter, to $31.1 million, primarily as a result of the acquisitions of
Vetstreet and ThinkPets."
2013 Financial Guidance
Based on the assumptions stated below, we provide the following
financial guidance for the full year 2013:
-
Revenue from $1.825 billion to $1.855 billion
-
Net income from $130 million to $139 million; and
-
Diluted earnings per common share from $1.45 to $1.55.
Our earning guidance excludes the impact of any acquisition related
expenses, the write off of any lease-hold or other real estate assets,
the impairment of intangible assets from prior acquisitions, or other
special, unusual or extraordinary items; assumes normal weather
conditions for the remainder of the year.
Conference Call
We will discuss our fourth quarter 2012 financial results during a
conference call today, February 14th, at 4:30 p.m. Eastern
Time. A live broadcast of the call may be accessed by visiting our
website at investor.vcaantech.com. The call
may also be accessed by dialing (877) 293-5492. Interested parties
should call at least 10 minutes prior to the start of the call to
register. Replay of the webcast will be available for ninety days by
visiting the company's website.
Forward-Looking Statements
This press release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995. Among
the forward-looking statements in this press release are statements
addressing our plans, expectations, future financial position and
results of operation. These forward-looking statements are not
historical facts and are inherently uncertain and out of our control.
Any or all of our forward-looking statements in this press release may
turn out to be wrong. They can be affected by inaccurate assumptions we
might make or by known or unknown risks and uncertainties. Actual future
results may vary materially. Among other factors that could cause our
actual results to differ from this forward-looking information are: our
ability to execute on our growth strategy and to manage acquired
operations; changes in demand for our products and services;
fluctuations in our revenue adversely affecting our gross profit,
operating income and margins; and the effects of the other factors
discussed in our Annual Report on Form 10-K for the year ended December
31, 2011, Reports on Form 10-Q and our other filings with the SEC.
About VCA Antech
We own, operate and manage the largest networks of freestanding
veterinary hospitals and veterinary-exclusive clinical laboratories in
the country. Additionally, we are the largest provider of online
communication, professional education and marketing solutions to the
veterinary community. We also supply diagnostic imaging equipment to the
veterinary industry.
|
|
|
|
|
|
|
|
|
VCA Antech, Inc.
|
|
Consolidated Income Statements
|
|
(Unaudited)
|
|
(In thousands, except per share amounts)
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended
|
|
|
Twelve Months Ended
|
|
|
|
|
December 31,
|
|
|
December 31,
|
|
|
|
|
2012
|
|
|
2011
|
|
|
2012
|
|
|
2011
|
|
Revenue:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Animal hospital
|
|
|
$
|
330,067
|
|
|
|
$
|
285,644
|
|
|
|
$
|
1,331,314
|
|
|
|
$
|
1,150,120
|
|
|
Laboratory
|
|
|
75,165
|
|
|
|
73,878
|
|
|
|
327,801
|
|
|
|
316,797
|
|
|
All other
|
|
|
31,117
|
|
|
|
26,243
|
|
|
|
112,960
|
|
|
|
80,430
|
|
|
Intercompany
|
|
|
(18,157
|
)
|
|
|
(16,767
|
)
|
|
|
(72,433
|
)
|
|
|
(61,986
|
)
|
|
|
|
|
418,192
|
|
|
|
368,998
|
|
|
|
1,699,642
|
|
|
|
1,485,361
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Direct costs
|
|
|
336,385
|
|
|
|
297,288
|
|
|
|
1,324,668
|
|
|
|
1,146,904
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Gross profit:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Animal hospital
|
|
|
39,923
|
|
|
|
35,727
|
|
|
|
189,111
|
|
|
|
179,810
|
|
|
Laboratory
|
|
|
31,737
|
|
|
|
31,063
|
|
|
|
151,761
|
|
|
|
143,790
|
|
|
All other
|
|
|
11,363
|
|
|
|
6,990
|
|
|
|
38,707
|
|
|
|
20,971
|
|
|
Intercompany
|
|
|
(1,216
|
)
|
|
|
(2,070
|
)
|
|
|
(4,605
|
)
|
|
|
(6,114
|
)
|
|
|
|
|
81,807
|
|
|
|
71,710
|
|
|
|
374,974
|
|
|
|
338,457
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Selling, general and administrative expense:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Animal hospital
|
|
|
8,029
|
|
|
|
6,089
|
|
|
|
30,826
|
|
|
|
24,342
|
|
|
Laboratory
|
|
|
7,267
|
|
|
|
7,287
|
|
|
|
29,660
|
|
|
|
27,864
|
|
|
All other
|
|
|
10,803
|
|
|
|
7,327
|
|
|
|
37,879
|
|
|
|
19,136
|
|
|
Corporate
|
|
|
15,400
|
|
|
|
15,075
|
|
|
|
58,790
|
|
|
|
49,770
|
|
|
|
|
|
41,499
|
|
|
|
35,778
|
|
|
|
157,155
|
|
|
|
121,112
|
|
|
Goodwill and other long-lived assets impairment
|
|
|
123,573
|
|
|
|
21,310
|
|
|
|
123,573
|
|
|
|
21,310
|
|
|
Net loss on sale of assets
|
|
|
288
|
|
|
|
425
|
|
|
|
1,310
|
|
|
|
382
|
|
|
Operating (loss) income
|
|
|
(83,553
|
)
|
|
|
14,197
|
|
|
|
92,936
|
|
|
|
195,653
|
|
|
Interest expense, net
|
|
|
3,806
|
|
|
|
4,068
|
|
|
|
16,552
|
|
|
|
16,884
|
|
|
Debt retirement costs
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
2,764
|
|
|
Business combination adjustment gain
|
|
|
-
|
|
|
|
-
|
|
|
|
(5,719
|
)
|
|
|
-
|
|
|
Other expense (income)
|
|
|
151
|
|
|
|
119
|
|
|
|
(488
|
)
|
|
|
118
|
|
|
(Loss) income before provision for income taxes
|
|
|
(87,510
|
)
|
|
|
10,010
|
|
|
|
82,591
|
|
|
|
175,887
|
|
|
Provision for income taxes
|
|
|
(30,485
|
)
|
|
|
12,070
|
|
|
|
31,875
|
|
|
|
76,027
|
|
|
Net (loss) income
|
|
|
(57,025
|
)
|
|
|
(2,060
|
)
|
|
|
50,716
|
|
|
|
99,860
|
|
|
Net income attributable to noncontrolling interests
|
|
|
1,026
|
|
|
|
1,155
|
|
|
|
5,165
|
|
|
|
4,455
|
|
|
Net (loss) income attributable to VCA Antech, Inc.
|
|
|
$
|
(58,051
|
)
|
|
|
$
|
(3,215
|
)
|
|
|
$
|
45,551
|
|
|
|
$
|
95,405
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Diluted (loss) earnings per share
|
|
|
$
|
(0.66
|
)
|
|
|
$
|
(0.04
|
)
|
|
|
$
|
0.51
|
|
|
|
$
|
1.09
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted-average shares outstanding for diluted earnings per share
|
|
|
88,060
|
|
|
|
86,829
|
|
|
|
88,671
|
|
|
|
87,394
|
|
|
|
|
|
|
|
|
|
|
VCA Antech, Inc.
|
|
Consolidated Balance Sheets
|
|
(Unaudited)
|
|
(In thousands)
|
|
|
|
|
|
|
|
|
|
|
|
|
December 31,
|
|
|
December 31,
|
|
|
|
|
2012
|
|
|
2011
|
|
Assets
|
|
|
|
|
|
|
|
Current assets:
|
|
|
|
|
|
|
|
Cash and cash equivalents
|
|
|
$
|
68,435
|
|
|
|
$
|
63,651
|
|
Trade accounts receivable, net
|
|
|
55,912
|
|
|
|
58,279
|
|
Inventory
|
|
|
51,456
|
|
|
|
48,661
|
|
Prepaid expenses and other
|
|
|
25,086
|
|
|
|
21,883
|
|
Deferred income taxes
|
|
|
26,667
|
|
|
|
26,310
|
|
Prepaid income taxes
|
|
|
20,061
|
|
|
|
18,373
|
|
Total current assets
|
|
|
247,617
|
|
|
|
237,157
|
|
Property and equipment, net
|
|
|
403,444
|
|
|
|
370,646
|
|
Other assets:
|
|
|
|
|
|
|
|
Goodwill
|
|
|
1,291,231
|
|
|
|
1,237,607
|
|
Other intangible assets, net
|
|
|
94,823
|
|
|
|
92,403
|
|
Notes receivable, net
|
|
|
6,080
|
|
|
|
6,202
|
|
Deferred financing costs, net
|
|
|
4,232
|
|
|
|
5,435
|
|
Other
|
|
|
48,241
|
|
|
|
45,918
|
|
Total assets
|
|
|
$
|
2,095,668
|
|
|
|
$
|
1,995,368
|
|
Liabilities and Equity
|
|
|
|
|
|
|
|
Current liabilities:
|
|
|
|
|
|
|
|
Current portion of long-term debt
|
|
|
$
|
35,057
|
|
|
|
$
|
32,571
|
|
Accounts payable
|
|
|
39,416
|
|
|
|
37,797
|
|
Accrued payroll and related liabilities
|
|
|
49,893
|
|
|
|
42,658
|
|
Other accrued liabilities
|
|
|
57,131
|
|
|
|
43,968
|
|
Total current liabilities
|
|
|
181,497
|
|
|
|
156,994
|
|
Long-term debt, less current portion
|
|
|
595,586
|
|
|
|
586,282
|
|
Deferred income taxes
|
|
|
79,934
|
|
|
|
101,229
|
|
Other liabilities
|
|
|
37,267
|
|
|
|
25,947
|
|
Total liabilities
|
|
|
894,284
|
|
|
|
870,452
|
|
Redeemable noncontrolling interests
|
|
|
6,991
|
|
|
|
6,964
|
|
VCA Antech, Inc. stockholders' equity:
|
|
|
|
|
|
|
|
Common stock
|
|
|
88
|
|
|
|
87
|
|
Additional paid-in capital
|
|
|
390,359
|
|
|
|
361,715
|
|
Retained earnings
|
|
|
791,209
|
|
|
|
745,658
|
|
Accumulated other comprehensive income
|
|
|
1,847
|
|
|
|
418
|
|
Total VCA Antech, Inc. stockholders' equity
|
|
|
1,183,503
|
|
|
|
1,107,878
|
|
Noncontrolling interests
|
|
|
10,890
|
|
|
|
10,074
|
|
Total equity
|
|
|
1,194,393
|
|
|
|
1,117,952
|
|
Total liabilities and equity
|
|
|
$
|
2,095,668
|
|
|
|
$
|
1,995,368
|
|
|
|
|
|
|
VCA Antech, Inc.
|
|
Consolidated Statements of Cash Flows
|
|
(Unaudited)
|
|
(In thousands)
|
|
|
|
|
Twelve Months Ended
|
|
|
|
|
December 31,
|
|
|
|
|
|
|
|
|
|
2012
|
|
|
2011
|
|
Cash flows from operating activities:
|
|
|
|
|
|
|
|
Net income
|
|
|
$
|
50,716
|
|
|
|
$
|
99,860
|
|
|
Adjustments to reconcile net income to net cash provided by
operating activities:
|
|
|
|
|
|
|
|
Goodwill and other long-lived assets impairment
|
|
|
123,573
|
|
|
|
21,310
|
|
|
Depreciation and amortization
|
|
|
76,227
|
|
|
|
56,988
|
|
|
Amortization of debt issue costs
|
|
|
1,278
|
|
|
|
1,445
|
|
|
Provision for uncollectible accounts
|
|
|
6,396
|
|
|
|
6,742
|
|
|
Debt retirement costs
|
|
|
-
|
|
|
|
2,764
|
|
|
Business combination adjustment gain
|
|
|
(5,719
|
)
|
|
|
-
|
|
|
Net loss on sale of assets
|
|
|
1,310
|
|
|
|
382
|
|
|
Share-based compensation
|
|
|
14,087
|
|
|
|
10,773
|
|
|
Deferred income taxes
|
|
|
(32,186
|
)
|
|
|
19,552
|
|
|
Excess tax benefit from exercise of stock options
|
|
|
(2,868
|
)
|
|
|
(1,708
|
)
|
|
Other
|
|
|
(584
|
)
|
|
|
(637
|
)
|
|
Changes in operating assets and liabilities:
|
|
|
|
|
|
|
|
Trade accounts receivable
|
|
|
1,640
|
|
|
|
(14,107
|
)
|
|
Inventory, prepaid expense and other assets
|
|
|
(10,329
|
)
|
|
|
(12,297
|
)
|
|
Accounts payable and other accrued liabilities
|
|
|
3,640
|
|
|
|
(5,415
|
)
|
|
Accrued payroll and related liabilities
|
|
|
7,181
|
|
|
|
4,583
|
|
|
Income taxes
|
|
|
2,891
|
|
|
|
816
|
|
|
Net cash provided by operating activities
|
|
|
237,253
|
|
|
|
191,051
|
|
|
Cash flows from investing activities:
|
|
|
|
|
|
|
|
Business acquisitions, net of cash acquired
|
|
|
(134,916
|
)
|
|
|
(205,794
|
)
|
|
Real estate acquired in connection with business acquisitions
|
|
|
(5,337
|
)
|
|
|
(1,900
|
)
|
|
Property and equipment additions
|
|
|
(76,807
|
)
|
|
|
(63,485
|
)
|
|
Proceeds from sale of assets
|
|
|
115
|
|
|
|
465
|
|
|
Other
|
|
|
(2,313
|
)
|
|
|
(596
|
)
|
|
Net cash used in investing activities
|
|
|
(219,258
|
)
|
|
|
(271,310
|
)
|
|
Cash flows from financing activities:
|
|
|
|
|
|
|
|
Repayment of debt
|
|
|
(60,775
|
)
|
|
|
(98,990
|
)
|
|
Proceeds from issuance of long-term debt
|
|
|
50,000
|
|
|
|
150,000
|
|
|
Proceeds from revolving credit facility
|
|
|
50,000
|
|
|
|
50,000
|
|
|
Repayment of revolving credit facility
|
|
|
(50,000
|
)
|
|
|
(50,000
|
)
|
|
Payment of financing costs
|
|
|
(122
|
)
|
|
|
(2,944
|
)
|
|
Distributions to noncontrolling interest partners
|
|
|
(4,481
|
)
|
|
|
(3,277
|
)
|
|
Proceeds from issuance of common stock under stock option plans
|
|
|
9,533
|
|
|
|
3,999
|
|
|
Excess tax benefit from exercise of stock options
|
|
|
2,868
|
|
|
|
1,708
|
|
|
Stock repurchases
|
|
|
(8,159
|
)
|
|
|
(2,673
|
)
|
|
Other
|
|
|
(2,378
|
)
|
|
|
(819
|
)
|
|
Net cash (used in) provided by financing activities
|
|
|
(13,514
|
)
|
|
|
47,004
|
|
|
Effect of currency exchange rate changes on cash and cash equivalents
|
|
|
303
|
|
|
|
(220
|
)
|
|
Increase (decrease) in cash and cash equivalents
|
|
|
4,784
|
|
|
|
(33,475
|
)
|
|
Cash and cash equivalents at beginning of period
|
|
|
63,651
|
|
|
|
97,126
|
|
|
Cash and cash equivalents at end of period
|
|
|
$
|
68,435
|
|
|
|
$
|
63,651
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
VCA Antech, Inc.
|
|
Supplemental Operating Data
|
|
(Unaudited - In thousands, except per share amounts)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Table #1
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Reconciliation of net income attributable to
|
|
|
|
Three Months Ended December 31,
|
|
|
|
|
Twelve Months Ended December 31,
|
|
VCA Antech, Inc., to adjusted net income
|
|
|
|
|
|
attributable to VCA Antech, Inc. (1)
|
|
|
2012
|
|
|
2011
|
|
|
2012
|
|
|
2011
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net (loss) income attributable to VCA Antech, Inc.
|
|
|
$
|
(58,051
|
)
|
|
|
$
|
(3,215
|
)
|
|
|
$
|
45,551
|
|
|
|
$
|
95,405
|
|
|
Goodwill and other long-lived assets impairment (2)
|
|
|
123,573
|
|
|
|
21,310
|
|
|
|
123,573
|
|
|
|
21,310
|
|
|
Tax benefit from goodwill and other long-lived assets impairment (2)
|
|
|
(44,353
|
)
|
|
|
-
|
|
|
|
(44,353
|
)
|
|
|
-
|
|
|
Debt retirement costs (3)
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
2,764
|
|
|
Tax benefit from debt retirement costs (3)
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
(1,082
|
)
|
|
Business combination adjustment gain (4)
|
|
|
-
|
|
|
|
-
|
|
|
|
(5,719
|
)
|
|
|
-
|
|
|
Depreciation expense adjustment (5)
|
|
|
-
|
|
|
|
-
|
|
|
|
3,051
|
|
|
|
-
|
|
|
Tax benefit from depreciation expense adjustment (5)
|
|
|
-
|
|
|
|
-
|
|
|
|
(1,194
|
)
|
|
|
-
|
|
|
Adjusted net income attributable to VCA Antech, Inc.
|
|
|
$
|
21,169
|
|
|
|
$
|
18,095
|
|
|
|
$
|
120,909
|
|
|
|
$
|
118,397
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Table #2
|
|
|
|
Three Months Ended December 31,
|
|
|
|
|
Twelve Months Ended December 31,
|
|
Reconciliation of diluted earnings per share to
|
|
|
|
|
|
adjusted diluted earnings per share (1)
|
|
|
2012
|
|
|
2011
|
|
|
2012
|
|
|
2011
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Diluted (loss) earnings per share
|
|
|
$
|
(0.66
|
)
|
|
|
$
|
(0.04
|
)
|
|
|
$
|
0.51
|
|
|
|
$
|
1.09
|
|
|
Impact of goodwill and other long-lived assets impairment, net of
tax(2)
|
|
|
0.90
|
|
|
|
0.25
|
|
|
|
0.89
|
|
|
|
0.24
|
|
|
Impact of debt retirement costs, net of tax (3)
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
0.02
|
|
|
Impact of business combination adjustment gain (4)
|
|
|
-
|
|
|
|
-
|
|
|
|
(0.06
|
)
|
|
|
-
|
|
|
Impact of depreciation expense adjustment, net of tax (5)
|
|
|
-
|
|
|
|
-
|
|
|
|
0.02
|
|
|
|
-
|
|
|
Adjusted diluted earnings per share
|
|
|
$
|
0.24
|
|
|
|
$
|
0.21
|
|
|
|
$
|
1.36
|
|
|
|
$
|
1.35
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Shares used for computing diluted loss per share
|
|
|
88,060
|
|
|
|
86,829
|
|
|
|
|
|
|
|
|
Shares used for computing adjusted
|
|
|
|
|
|
|
|
|
|
|
|
|
|
diluted earnings per share
|
|
|
88,914
|
|
|
|
87,531
|
|
|
|
88,671
|
|
|
|
87,394
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Table #3
|
|
|
|
Three Months Ended December 31,
|
|
|
|
|
Twelve Months Ended December 31,
|
|
Reconciliation of operating income to
|
|
|
|
|
|
adjusted operating income (1)
|
|
|
2012
|
|
|
2011
|
|
|
2012
|
|
|
2011
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Consolidated operating (loss) income
|
|
|
$
|
(83,553
|
)
|
|
|
$
|
14,197
|
|
|
|
$
|
92,936
|
|
|
|
$
|
195,653
|
|
|
Impact of goodwill and other long-lived assets impairment (2)
|
|
|
123,573
|
|
|
|
21,310
|
|
|
|
123,573
|
|
|
|
21,310
|
|
|
Impact of depreciation expense adjustment (5)
|
|
|
-
|
|
|
|
-
|
|
|
|
3,051
|
|
|
|
|
|
Consolidated adjusted operating income
|
|
|
$
|
40,020
|
|
|
|
$
|
35,507
|
|
|
|
$
|
219,560
|
|
|
|
$
|
216,963
|
|
|
Consolidated adjusted operating margin
|
|
|
9.6
|
%
|
|
|
9.6
|
%
|
|
|
12.9
|
%
|
|
|
14.6
|
%
|
|
_________________________________________________
|
|
(1)
|
|
|
Management uses adjusted net income, adjusted diluted earnings per
share, and adjusted gross profit and its components, among other
factors, to measure the performance of the overall Company. Further,
we believe that investors' understanding of our performance is
enhanced by disclosing these measures. Adjusted net income and its
components and adjusted diluted EPS measures are not, and should not
be viewed as substitutes for, U.S. generally accepted accounting
principles (GAAP) net income and its components and diluted earnings
per share.
|
|
|
|
|
|
|
(2)
|
|
|
During the fourth quarter of 2012, we recorded a non-cash impairment
charge of $123.6 million, of which $122.4 million relates to the
write-down of goodwill and other long-lived assets in our Vetstreet
business, reported in our All Other segment. In the prior-year
quarter, we recorded a non-cash impairment charge of $21.3 million
related to the write-down of goodwill in our Medical Technology
business, also reported in our All Other segment.
|
|
|
|
|
|
|
(3)
|
|
|
During the prior year, we incurred debt retirement costs related to
the refinancing of our senior credit facility. The rate used to
calculate the tax benefit is the statutory rate of the applicable
year.
|
|
|
|
|
|
|
(4)
|
|
|
As a result of the acquisition of a controlling interest in AVC, we
recorded a gain for the increase in value of our previously held
interest in AVC, which we acquired in 2008.
|
|
|
|
|
|
|
(5)
|
|
|
Due to corrections in the calculation of depreciation on certain
assets, we recognized an additional depreciation expense during the
second quarter. The rate used to calculate the tax benefit is the
statutory rate of the applicable year.
|
|
|
|
|
|
|
|
|
|
|
|
|
VCA Antech, Inc.
|
|
Supplemental Operating Data (continued)
|
|
(Unaudited - In thousands, except per share amounts)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
As of
|
|
|
|
|
|
|
|
|
|
|
December 31,
|
|
|
December 31,
|
|
Table #4
|
|
|
|
|
|
|
|
|
2012
|
|
|
2011
|
|
Selected consolidated balance sheet data
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Debt:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Senior term notes
|
|
|
|
|
|
|
|
|
$
|
592,422
|
|
|
|
$
|
573,984
|
|
|
Other debt and capital leases
|
|
|
|
|
|
|
|
|
38,221
|
|
|
|
44,869
|
|
|
Total debt
|
|
|
|
|
|
|
|
|
$
|
630,643
|
|
|
|
$
|
618,853
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended December 31,
|
|
|
|
|
Twelve Months Ended December 31,
|
|
Table #5
|
|
|
|
|
|
Selected expense data
|
|
|
2012
|
|
|
2011
|
|
|
2012
|
|
|
2011
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Rent expense
|
|
|
$
|
17,105
|
|
|
|
$
|
14,853
|
|
|
|
$
|
66,032
|
|
|
|
$
|
55,190
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Depreciation and amortization included in direct costs:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Animal hospital
|
|
|
$
|
13,865
|
|
|
|
$
|
10,429
|
|
|
|
$
|
53,932
|
|
|
|
$
|
39,973
|
|
|
Laboratory
|
|
|
2,431
|
|
|
|
2,464
|
|
|
|
9,775
|
|
|
|
9,696
|
|
|
All other
|
|
|
1,172
|
|
|
|
301
|
|
|
|
6,485
|
|
|
|
2,431
|
|
|
Intercompany
|
|
|
(427
|
)
|
|
|
(364
|
)
|
|
|
(1,529
|
)
|
|
|
(1,317
|
)
|
|
|
|
|
$
|
17,041
|
|
|
|
$
|
12,830
|
|
|
|
$
|
68,663
|
|
|
|
$
|
50,783
|
|
|
Depreciation and amortization included in selling, general and
administrative expense
|
|
|
2,304
|
|
|
|
2,772
|
|
|
|
7,564
|
|
|
|
6,205
|
|
|
Total depreciation and amortization
|
|
|
$
|
19,345
|
|
|
|
$
|
15,602
|
|
|
|
$
|
76,227
|
|
|
|
$
|
56,988
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Share-based compensation included in direct costs:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Laboratory
|
|
|
$
|
86
|
|
|
|
$
|
99
|
|
|
|
$
|
330
|
|
|
|
$
|
410
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Share-based compensation included in selling, general and
administrative expense:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Animal hospital
|
|
|
291
|
|
|
|
271
|
|
|
|
1,049
|
|
|
|
1,148
|
|
|
Laboratory
|
|
|
294
|
|
|
|
359
|
|
|
|
1,141
|
|
|
|
1,279
|
|
|
All other
|
|
|
166
|
|
|
|
227
|
|
|
|
602
|
|
|
|
428
|
|
|
Corporate
|
|
|
2,784
|
|
|
|
3,207
|
|
|
|
10,965
|
|
|
|
7,508
|
|
|
|
|
|
3,535
|
|
|
|
4,064
|
|
|
|
13,757
|
|
|
|
10,363
|
|
|
Total share-based compensation
|
|
|
$
|
3,621
|
|
|
|
$
|
4,163
|
|
|
|
$
|
14,087
|
|
|
|
$
|
10,773
|
|

[ Back To education 's Homepage ]
|